Female sex hormones and cardiovascular disease in women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 12, 1997, Pages 3913-3918

  Skafar, Debra F ^a   Xu, Rui ^a   Morales, Juan ^a   Ram, Jeffrey ^a   Sowers, James R ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE; ESTRADIOL; SEX HORMONE;

CARDIOVASCULAR DISEASE; CORONARY RISK; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; PRIORITY JOURNAL; PROGESTERONE METABOLISM; REVIEW; BLOOD VESSEL; DRUG COMBINATION; DRUG EFFECT;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; PROGESTERONE;

EID: 0031307588     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.12.3913     Document Type: Review

References (137)

1. Lerner DJ, Kannel WB. 1986 Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 3:393-390.
2. National Center for Health Statistics. 1988 Vital statistics of the United States 1986. II. Mortality, A and B. Washington DC: US Department of Health and Human Services; publications 88-1122 and 88-1113.
3. Barrett-Connor E, Bush TL. 1991 Estrogen and coronary heart disease in women. JAMA. 265:1861-1867.
4. Hanes DS, Weir MR, Sowers JR. 1996 Gender considerations in hypertension pathophysiology and treatment. Am J Med. 101:10S-21S.
5. Bush TL, Barrett-Conner E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM. 1987 Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 75:1182-1189.
6. Sullivan JM, Van der Zwaag R, Lemp GF, Hughes JP, Maddock V, Kroetz FW. 1988 Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 108:358-363.
7. Gruchow HW, Anderson AJ, Barboriak JJ. 1988 Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 115:954-963.
8. Wilson PW, Garrison RJ, Castelli WP. 1985 Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 313:1038-1043.
9. Sullivan JM, Zwaag VR, Hughes J. 1990 Effect of estrogen replacement and coronary artery disease on survival in postmenopausal women. Arch Intern Med. 150:2557-2562.
10. Wolf PH, Madans JH, Finucane FF. 1991 Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol. 164:489-494.
11. Barrett-Connor E. 1991 Postmenopausal estrogen and prevention bias. Ann Intern Med. 115:455-456.
12. Tsevat J, Weinstein MC, Williams LW. 1991 Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 83:1194-1201.
13. 2 replacement therapy: a decision analysis. Obstet Gynecol. 83:161-166.
14. Stampfer MJ, Colditz GA, Willet WC, Munson JE, Rosner B, Speizer FE. 1991 Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 325:756-762.
15. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. 1992 Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol. 69:176-178.
16. Grady D, Rubin SM, Petitti DB, et al. 1992 Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1016-1037.
17. Psaty BM, Heckbert SR, Atkins D. 1994 The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 154:1333-1339.
18. Rosenberg L, Palmer JR, Shapiro S. 1993 A case control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 137:54-63.
19. The Writing Group for the PEPI Trial. 1995 Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:199-208.
20. Rosano GM, Sarrell PM, Poole-Wilson PA, Collins P. 1993 Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet. 342:133-136.
21. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. 1994 Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br Med J. 308:1268-1269.
22. Boysen G, Nyboe J, Appleyard M. 1998 Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 19:1345-1353.
23. Paganini-Hill A, Ross RK, Henderson BE. 1988 Postmenopausal oestrogen treatment and stroke: a prospective study. Br Med J. 297:519-522.
24. The American-Canadian Co-Operative Study Group. 1986 Persantine aspirin trial in cerebral ischemia. III. Risk factors for stroke. Stroke. 17:12-18.
25. Finucane FF, Maduns JH, Bush TL, Wolf PH, Kleinman JC. 1993 Decreased risk factor of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 153:73-39.
26. Grodstein F, Stampfer MJ, Manson JE. 1996 Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 15:453-461.
27. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. 1987 Long-term effects of percutaneous estrogens, and progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 156:66-71.
28. Sherwin BB, Gelfand MM. 1989 A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol. 73:759-766.
29. Miller VT, Muesing RA, LaRosa JC. 1991 Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subtractions, and apolipoprotein A-1. Obstet Gynecol. 77:235-240.
30. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1196-1204.
31. Lobo RA. 1991 Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 73:925-930.
32. Tikkanen MJ. 1990 Role of lipoproteins in the pathogenesis of atherosclerotic disease with special reference to sex hormone effects. Am J Obstet Gynecol. 163:296-304.
33. Van der Mooren MJ, Demacker PNM, Thomas CMG. 1992 Beneficial effects on serum lipoproteins by 17β-estradiol-dydrogesterone therapy in postmenopausal women: a prospective study. Eur J Obstet Gynecol Reprod Biol. 47:153-160.
34. Soma MR, Osnago-Gadda I, Paoletti R. 1993 The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 153:1462-1468.
35. Walsh BW, Sacks FM. 1993 Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest. 91:2126-2132.
36. Nabulsi AA, Folsom AR, White A. 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 328:1069-1075.
37. Moorjani S, Dupont A, Abrie F. 1991 Changes in plasma lipoprotein and apolipoprotein composition in relation to oral vs. percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab. 73:373-379.
38. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S. 1986 Post-menopausal hormone replacement therapy: effects of progestogens on serum lipids, and lipoproteins: a review. Maturitas. 8:7-17.
39. Sherwin BB, Gelfand MM. 1989 A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol. 73:759-766.
40. Adams MR, Clarkson TB, Shively CA. 1990 Oral contraceptives, lipoproteins, and atherosclerosis. Am J Obstet Gynecol. 163:1388-1393.
41. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. 1994 Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol. 84:987-995.
42. Rosselli M, Imthurn B, Keller PJ, Dubey RK. 1995 Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate. A two year follow-up study. Hypertension. 25:848-853.
43. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. 1997 Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 3:324-327.
44. Evans RM. 1988 The steroid and thyroid hormone receptor superfamily. Science. 240:889-895.
45. Beato M, Chavez S, Truss M. 1996 Transcriptional regulation by steroid hormones. Steroids. 61:240-251.
46. Smith D, Toft D. 1993 Steroid receptors and their associated proteins. Mol Endocrinol. 7:4-11.
47. Pratt WB, Gehring U, Toft DO. 1996 Molecular chaperoning of steroid hormone receptors. In: Feige U, Morimoto RI, Yahara I, Polla B, eds. Stress-inducible cellular responses. Basel, Switzerland: Birkhauser Verlag; 79-95.
48. Skafar DF, Notides AC. 1985 Modulation of the estrogen receptor's affinity for DNA by estradiol. J Biol Chem. 260:12208-12213.
49. Kumar V, Chambon P. 1988 The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell. 55:145-156.
50. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1354-1357.
51. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:3667-3675.
52. Green S, Walter P, Kumar V, et al. 1986 Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 320:134-139.
53. Greene GL, Gilna P, Waterfield BA, Baker A, Hort Y, Shine J. 1986 Sequence and expression of human estrogen receptor complementary DNA. Science. 231:1150-1154.
54. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925-5930.
55. Mosselman S, Polman J, Dijkema R. 1996 ERβ: identification, and characterization of a novel human estrogen receptor. FEBS Lett. 392:49-53.
56. Tremblay BG, Tremblay A, Copeland NG, et al. 1997 Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor B. Mol Endocrinol. 11:353-365.
57. Iafrate MD, Karas RH, Aronovitz M, et al. 1997 Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med. 3:545-548.
58. McGill HC, Sheridan PJ. 1980 Nuclear uptake of sex steroid hormones in the cardiovascular system of the baboon. Circ Res. 48:238-244.
59. Colburn P, Buonassissi V. 1978 Estrogen-binding sites in endothelial cell cultures. Science. 201:817-819.
60. Harder DR, Coulson PB. 1979 Estrogen receptor and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol. 100:375-382.
61. Nakao J, Chang WC, Murota SI, Orimo H. 1981 Estradiol-binding sites in rat aortic smooth muscle cells in culture. Atherosclerosis. 38:75-80.
62. Horwitz KB, Horwitz LD. 1982 Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids. J Clin Invest. 69:750-758.
63. 2 receptor distribution and elevates P receptor content in baboon aorta. Arteriosclerosis. 6:495-504.
64. Tamaya T, Misao R, Nakagawa M, et al. 1993 Estradiol and androgen receptors in aorta of the rabbit and regulation by estradiol and androgen. Res Commun Chem Pathol Pharmacol. 82:3-11.
65. Orimo A, Inoue S, Ikegami A, et al. 1993 Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun. 195:730-736.
66. Bayard F, Clemens S, Meggetto F, Blaes N, Delsol G, Faye JC. 1995 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology. 136:1523-1529.
67. Karas RH, Patterson BL, Medelsohn ME. 1994 Human vascular smooth muscle cells contain functional estrogen receptor. Circulation. 89:1943-1950.
68. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. 1994 Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 89:1501-1510.
69. Knauthe R, Diel P, Hagele-Haratung C, Engelhaapt A, Fritzemeir K. 1996 Sexual dimorphism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology. 137:3220-3227.
70. Campisi D, Cutolo M, Carruba G, et al. 1993 Evidence for soluble and nuclear site I binding of estradiol in human aorta. Atherosclerosis. 103:267-277.
71. Lin AL, Gonzalez R, Carey KD, Shain SA. 1987 Gender and baboon aortic steroid hormone receptors. Atheriosclerosis. 7:248-255.
72. Oparil S, Levin RL, Chen YF. 1996 Sex hormones and the vasculature. In: Sowers JR, ed. Endocrinology of the vasculature. Totowa: Humana Press; 225-238.
73. Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. 1993 Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol. 109:612-617.
74. Leibermann JR, van Vroonhoven CO, Beckmann I, van der Kwast TH, Wallenberg HCS. 1990 Uterine artery estrogen receptors in the nonpregnant and pregnant guinea pig. Am J Obstet Gynecol. 163:1685-1688.
75. + currents in A7r5 VSMC line. Am J Physiol. 266:C975-C980.
76. Cheng DY, Gruetter CA. 1992 Chronic estrogen alters contractile responsiveness to angiotensin 11 and norepinephrine in female rat aorta. Eur J Pharmacol. 215:171-176.
77. Jie S, Resnick LM, Liu Q-Y, Wu X-C, Barbagallo M, Pang PKT. 1994 Vascular effects of 17β estradiol in male Sprague-Dawley rats. Am J Physiol. 266:H967-H973.
78. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. 1992 Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 263:H271-H275.
79. De Beer EL, Keizer HA. 1982 Direct action of estradiol-17β on the atrial action potential. Steroids. 40:223-231.
80. Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT. 1992 Effect of 17β-estradiol on contraction, calcium current and intracellular free calcium in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 106:739-745.
81. Rosenfeld CR, Jackson GM. 1984 Estrogen-induced refractoriness to the pressor effects of infused angiotensin II. Am J Obstet Gynecol. 148:429-435.
82. Harder DR, Coulson PB. 1979 Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol. 100:375-382.
83. Ca, channels through a cGMP-dependent mechanism. Circ Res. 77:936-942.
84. Wellman GC, Brayden JE, Nelson MT. 1996 A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clin Exp Pharmacol Physiol. 23:260-266.
85. Darkow DJ, Lu L, White RE. 1997 Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol. 272:H2765-H2773.
86. + channels. Circ Res. 79:1024-1030.
87. + channels in coronary vasodilation induced by 17β-estradiol in ischemic heart failure. FASEB J. 11:793-799.
88. Arnold WP, Mittal CK, Katsuki S, Murad F. 1977 Nitric oxide activates guanylate cyclase and increases guanosine 3′-5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA. 3203-3207.
89. + channels in vascular smooth muscle cells. Proc Natl Acad Sci USA. 85:9360-9364.
90. + channels are stimulated by cyclic guanosine monophosphate-dependent protein kinase in canine coronary artery smooth muscle cells. Pflugers Arch. 423:167-172.
91. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. 1994 Nitric oxide directly activates potassium channels in vascular smooth muscle. Nature. 368:850-853.
92. Fischer-Dzoga K, Wissler RW, Vesselinovitch D. 1983 The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipernic serum. Exp Mol Pathol. 39:355-363.
93. Farhat MY. 1996 The vascular protective effects of estrogen. FASEB J. 10:615-624.
94. Moragham T, Antonucci DM, Grinert JP, et al. 1996 Differential response in cell proliferation to beta estradiol in coronary arterial vascular smooth muscle cells obtained form mature female vs. male animals. Endocrinology. 137:5174-5177.
95. Foegh M, Asotra S, Howell M, Ramwell P. 1994 Estradiol inhibition of arterial neointimal hyperplasmia after balloon injury. J Vasc Surg. 19:722-726.
96. Chen SJ, Li H, Durand J, Oparil S, Chen YF. 1996 BE2 reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 93:577-584.
97. Sullivan Jr TR, Karas RH, Aronovitz M, et al. 1995 Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 96:2482-2488.
98. Gisclard V, Miller VM, Vanhoutte PM. 1988 Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 244:19-22.
99. Miller VM, Gisclard V, Vanhoutte PM. 1988 Modulation of endothelium-dependent and vascular smooth muscle responses by estrogens. Phlebologie. 3:63-69.
100. Williams JK, Adams MR, Herrington DM, Clarkson TB. 1992 Short-term administration of estrogen, and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 20:452-457.
101. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. 1994 Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:786-791.
102. Sudher K, Jennings JL, Funder JW, Komesaroff PA. 1996 Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women. Hypertension. 28:330-334.
103. Gilligan DM, Quyyumi AA, Cannon RO. 1994 Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:2545-2551.
104. Rosenfeld CR, Cox BE, Roy T, Magness RR. 1996 Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation. J Clin Invest. 98:2158-2166.
105. Lieberman EH, Gerhard MD, Uehata A, et al. 1994 Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:936-941.
106. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. 1992 Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA. 89:11259-11263.
107. Rubanyi GM, Freay AD, Kauser K, et al. 1997 Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. J Clin Invest. 99:2429-2437.
108. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. 1994 Induction of calcium-dependent nitric oxide syntheses by sex hormones. Proc Natl Acad Sci USA. 91:5212-5216.
109. Hayashi T. 1995 Estrogen increased endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun. 214:847-855.
110. Hishikawa K. 1995 Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 360:291-293.
111. Garg UC, Hassid A. 1989 Nitric oxide generating vasodilators and 8-bromocyclic guanosine and monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1774-1777.
112. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin F. 1991 Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb. 11:254-260.
113. Radomski MW, Palmer RM, Moncada S. 1987 Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1057-1058.
114. Morales DE, McGowan KA, Grant DS, et al. 1995 Estrogen promotes angiogenesis activity in human umbilical vein endothelial cells in vitro and in a murine model. Circ Res. 91:755-763.
115. Johns A, Freay AD, Fraser W, Korach KS, Rubanyi GM. 1996 Disruption of estrogen receptor gene prevents 17β-estradiol-induced angiogenesis in transgenic mice. Endocrinology. 137:4511-4513.
116. Cid MC, Kleinman HK, Grant DS, et al. 1994 Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intracellular adhesion molecule type 1 and vascular cell adhesion molecule type 1. J Clin Invest. 93:17-25.
117. Sheweiki D, Itin A, Neufeld G, et al. 1993 Patterns of expression of vascular endothelial growth factor (VEGF) and VEGT receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 91:2235-2243.
118. Asahara T, Baulera C, Pastore C, et al. 1995 Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intinial hyperplasia in balloon-injured rat carotid artery. Circ Res. 91:2793-2801.
119. Christensen K, Estes PA, Onate SA, et al. 1991 Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. Mol Endocrinol. 5:1755-1770.
120. Tetel MJ, Jung S, Carbajo P, Ladtkow T, Skafar DF, Edwards DP. 1997 Hinge and amino-terminal sequences contribute to solution dimerization of human progesterone receptor. Mol Endocrinol. 11:1114-1128.
121. Vegeto E, Shabaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol. 7:1244-1255.
122. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements, and are dominantly inhibited by A-receptors. Mol Endocrinol. 7:1256-1265.
123. McDonnell DP, Goldman ME. 1994 RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem. 269:11945-11949.
124. Wen DW, Xu Y-F, Mais DE, Goldman ME, McDonnell DP. 1994 The A, and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol. 14:8356-8364.
125. Wiehle RD, Manga R, Poindexter III AM, Weigel NL. Human progesterone receptor A and B expression during the menstrual cycle. Proc of the 7th Annual Meet of The Endocrine Soc. 1995; 224.
126. Kraus WL, Montane MM, Katzenllenbogen T. 1988 Identification of multiple, widely spaced estrogen-response regions in the rat progesterone receptor gene. Mol Endocrinol. 8:952-969.
127. Samsioe G. 1994 The endometrium: effects of estrogen and estrogen-progestogen replacement therapy. Int J Fertil Menopausal Studies. 39(Suppl 2):84-92.
128. King RJ, William L. McGuire Memorial Symposium. 1993 Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res Treat. 27:3-15.
129. Shi YE, Liu YE, Lippman ME, Dickson RB. 1994 Progestins and antiprogestins in mammary tumour growth and metastasis. Hum Reprod. 9(Suppl 1):162-173.
130. Miller VM, Vanhoutte PM. 1991 Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol. 261:R1022-R1027.
131. Hanke H, Hanke S, Bruck B, et al. 1996 Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis. 121:129-138.
132. Hanke H, Hanke S, Finking G, et al. 1996 Different effects of estrogen and progesterone on experimental atherosclerosis in female vs. male rabbits. Quantification of cellular proliferation by bromodeoxyuridine. Circulation. 94:175-181.
133. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH. 1996 Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progestins, in the human endometrium. J Clin Invest. 97:403-412.
134. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. 1992 Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol. 211:163-167.
135. Raman BB, Standley PR, Rajkumar V, Ram JL, Sowers JR. 1995 Effects of estradiol and progesterone on platelet calcium responses. Am J Hypertens. 8:197-200.
136. McCrohon JA, Adams MR, McCredie RJ, et al. 1996 Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Clin Endocrinol (Oxf). 45:435-441.
137. Koh KK, Mincemoyer R, Bui MN, et al. 1997 Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336:683-690.